tetano
Editor, Senior Moderator
BMC Immunol
. 2024 Jan 13;25(1):5.
doi: 10.1186/s12865-024-00596-1. IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
Huan Xie[SUP] #[/SUP][SUP] 1 [/SUP], Jing Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Ran Luo[SUP] 1 [/SUP], Yan Qi[SUP] 1 [/SUP], Yizhang Lin[SUP] 1 [/SUP], Changhao Han[SUP] 1 [/SUP], Xi Li[SUP] 2 [/SUP], Dongfeng Zeng[SUP] 3 [/SUP]
Affiliations
Background: The ability of generating effective humoral immune responses to SARS-CoV-2 infection has not been clarified in lymphoma patients. The study aimed to investigate the antibody (Ab) production after SARS-Cov-2 infection and clarify the factors affecting the Ab generation in these patients.
Patients & methods: 80 lymphoma patients and 51 healthy controls were included in this prospective observational study. Clinical factors and treatment regimens affecting Ab positive rate (APR) and Ab levels were analyzed by univariate and multivariate methods.
Results: The anti-SARS-CoV-2 IgG APR and Ab levels in lymphoma patients were significantly lower than those in healthy controls. Lymphoma patients with COVID-19 vaccination had significantly higher APR and Ab levels compared with those without vaccination. Additionally, the use of dexamethasone for COVID-19 treatment had a negative impact on Ab levels. For the impact of treatment regimens on the APR and Ab levels, the results showed that patients treated with ≥ 6 times CD20 monoclonal Ab (mAb) and patients treated with autologous hematopoietic stem cell transplantation (ASCT) prior to infection produced a statistically lower APR and Ab levels compared with those treated with 1-5 times CD20 mAb and those treated without ASCT, respectively. Furthermore, multiple regression analysis indicated that the number of anti-CD20 treatment was an independent predictor for both APR and Ab levels.
Conclusions: Humoral immune response to SARS-CoV-2 infection was impaired in lymphoma patients partly due to anti-CD20 and ASCT treatment. COVID-19 vaccination may be more needed for these patients.
Keywords: Antibody; CD20; COVID-19; Lymphoma; SARS-CoV-2.
. 2024 Jan 13;25(1):5.
doi: 10.1186/s12865-024-00596-1. IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
Huan Xie[SUP] #[/SUP][SUP] 1 [/SUP], Jing Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Ran Luo[SUP] 1 [/SUP], Yan Qi[SUP] 1 [/SUP], Yizhang Lin[SUP] 1 [/SUP], Changhao Han[SUP] 1 [/SUP], Xi Li[SUP] 2 [/SUP], Dongfeng Zeng[SUP] 3 [/SUP]
Affiliations
- PMID: 38218761
- PMCID: PMC10788029
- DOI: 10.1186/s12865-024-00596-1
Background: The ability of generating effective humoral immune responses to SARS-CoV-2 infection has not been clarified in lymphoma patients. The study aimed to investigate the antibody (Ab) production after SARS-Cov-2 infection and clarify the factors affecting the Ab generation in these patients.
Patients & methods: 80 lymphoma patients and 51 healthy controls were included in this prospective observational study. Clinical factors and treatment regimens affecting Ab positive rate (APR) and Ab levels were analyzed by univariate and multivariate methods.
Results: The anti-SARS-CoV-2 IgG APR and Ab levels in lymphoma patients were significantly lower than those in healthy controls. Lymphoma patients with COVID-19 vaccination had significantly higher APR and Ab levels compared with those without vaccination. Additionally, the use of dexamethasone for COVID-19 treatment had a negative impact on Ab levels. For the impact of treatment regimens on the APR and Ab levels, the results showed that patients treated with ≥ 6 times CD20 monoclonal Ab (mAb) and patients treated with autologous hematopoietic stem cell transplantation (ASCT) prior to infection produced a statistically lower APR and Ab levels compared with those treated with 1-5 times CD20 mAb and those treated without ASCT, respectively. Furthermore, multiple regression analysis indicated that the number of anti-CD20 treatment was an independent predictor for both APR and Ab levels.
Conclusions: Humoral immune response to SARS-CoV-2 infection was impaired in lymphoma patients partly due to anti-CD20 and ASCT treatment. COVID-19 vaccination may be more needed for these patients.
Keywords: Antibody; CD20; COVID-19; Lymphoma; SARS-CoV-2.